Clinical utility of 18F-FDG PET parameters in patients with advanced nasopharyngeal carcinoma: Predictive role for different survival endpoints and impact on prognostic stratification

Nuclear Medicine Communications

Volumn 32, Issue 11, 2011, Pages 989-996

  Chan, Sheng Chieh ^a   Chang, Joseph T ^a   Lin, Chien Yu ^a   Ng, Shu Hang ^a   Wang, Hung Ming ^a   Liao, Chun Ta ^a   Chang, Chee Jen ^a,b   Lin, Shao Yu ^a   Yen, Tzu Chen ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

fluoro 2 deoxy D glucose positron emission tomography; metabolic tumor volume; nasopharyngeal carcinoma; standardized uptake value; total lesion glycolysis

Indexed keywords

CISPLATIN; FLUORODEOXYGLUCOSE F 18; FOLINIC ACID; UFT; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; ADVANCED CANCER; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CERVICAL LYMPH NODE; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GLYCOLYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; MULTIMODALITY CANCER THERAPY; NASOPHARYNX CARCINOMA; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PREMEDICATION; PRIMARY TUMOR; PROGNOSIS; PROSPECTIVE STUDY; SCORING SYSTEM; SEX DIFFERENCE; TUMOR VOLUME; AGED; LYMPH NODE; LYMPH NODE METASTASIS; METASTASIS; METHODOLOGY; MIDDLE AGED; MORTALITY; NASOPHARYNX TUMOR; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SCINTISCANNING; SQUAMOUS CELL CARCINOMA; SURVIVAL; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 80053565407     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3283495662     Document Type: Article

References (33)

1. Marks JE, Phillips JL, Menck HR. The National Cancer Data Base report on the relationship of race and national origin to the histology of nasopharyngeal carcinoma. Cancer 1998; 83:582-588. (Pubitemid 28354516)
2. Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet 2005; 365: 2041-2054. (Pubitemid 40812341)
3. Greene FLPI, Fritz AG, Balch CM, Haller DG, Monica M. AJCC Cancer Staging Manual. 9th ed. New York: Springer-Verlag; 2002.
4. OSullivan B. Nasopharynx cancer: therapeutic value of chemoradiotherapy. Int J Radiat Oncol Biol Phys 2007; 69:S118-S121.
5. Chan SC, Chang JT,Wang HM, Lin CY, Ng SH, Fan KH, et al. Prediction for distant failure in patients with stage M0 nasopharyngeal carcinoma: the role of standardized uptake value. Oral Oncol 2009; 45:52-58.
6. Lee SW, Nam SY, Im KC, Kim JS, Choi EK, Ahn SD, et al. Prediction of prognosis using standardized uptake value of 2-[(18)F] fluoro-2-deoxy-D-glucose positron emission tomography for nasopharyngeal carcinomas. Radiother Oncol 2008; 87:211-216.
7. Chung MK, Jeong HS, Park SG, Jang JY, Son YI, Choi JY, et al. Metabolic tumor volume of [18F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts short-term outcome to radiotherapy with or without chemotherapy in pharyngeal cancer. Clin Cancer Res 2009; 15:5861-5868.
8. La TH, Filion EJ, Turnbull BB, Chu JN, Lee P, Nguyen K, et al. Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2009; 74:1335-1341.
9. Seol YM, Kwon BR, Song MK, Choi YJ, Shin HJ, Chung JS, et al. Measurement of tumor volume by PET to evaluate prognosis in patients with head and neck cancer treated by chemo-radiation therapy. Acta Oncol 2010; 49:201-208.
10. Larson SM, Erdi Y, Akhurst T, Mazumdar M, Macapinlac HA, Finn RD, et al. Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. the visual response score and the change in total lesion glycolysis. Clin Positron Imaging 1999; 2:159-171.
11. Benz MR, Allen-Auerbach MS, Eilber FC, Chen HJ, Dry S, Phelps ME, et al. Combined assessment of metabolic and volumetric changes for assessment of tumor response in patients with soft-tissue sarcomas. J Nucl Med 2008; 49:1579-1584.
12. Francis RJ, Byrne MJ, Van der Schaaf AA, Boucek JA, Nowak AK, Phillips M, et al. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volumebased analysis of serial 18F-FDG PET scans. J Nucl Med 2007; 48: 1449-1458. (Pubitemid 47397395)
13. Guillem JG, Moore HG, Akhurst T, Klimstra DS, Ruo L, Mazumdar M, et al. Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: a means for determining longterm outcomes of rectal cancer. J Am Coll Surg 2004; 199:1-7. (Pubitemid 38813288)
14. Roedl JB, Colen RR, Holalkere NS, Fischman AJ, Choi NC, Blake MA. Adenocarcinomas of the esophagus: response to chemoradiotherapy is associated with decrease of metabolic tumor volume as measured on PETCT Comparison to histopathologic and clinical response evaluation. Radiother Oncol 2008; 89:278-286.
15. Yau TK, Lee AW, Wong DH, Yeung RM, Chan EW, Ng WT, et al. Induction chemotherapy with cisplatin and gemcitabine followed by accelerated radiotherapy and concurrent cisplatin in patients with stage IV(A-B) nasopharyngeal carcinoma. Head Neck 2006; 28:880-887. (Pubitemid 44497863)
16. Lee AW, Lau KY, Hung WM, Ng WT, Lee MC, Choi CW, et al. Potential improvement of tumor control probability by induction chemotherapy for advanced nasopharyngeal carcinoma. Radiother Oncol 2008; 87:204-210.
17. Hong RL, Ting LL, Ko JY, Hsu MM, Sheen TS, Lou PJ, et al. Induction chemotherapy with mitomycin, epirubicin, cisplatin, fluorouracil, and leucovorin followed by radiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol 2001; 19:4305-4313.
18. Wang HM, Hsueh CT, Wang CS, Chen IH, Liao CT, Tsai MH, et al. Phase II trial of cisplatin, tegafur plus uracil and leucovorin as neoadjuvant chemotherapy in patients with squamous cell carcinoma of the oropharynx and hypopharynx. Anticancer Drugs 2005; 16:447-453.
19. Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998; 16:1310-1317. (Pubitemid 28175745)
20. Marcial VA, Pajak TF, Mohiuddin M, Cooper JS, Al Sarraf M, Mowry PA, et al. Concomitant cisplatin chemotherapy and radiotherapy in advanced mucosal squamous cell carcinoma of the head and neck. Long-term results of the Radiation Therapy Oncology Group study 81-17. Cancer 1990; 66: 1861-1868.
21. Xie P, Yue JB, Zhao HX, Sun XD, Kong L, Fu Z, et al. Prognostic value of 18F-FDG PET-CT metabolic index for nasopharyngeal carcinoma. J Cancer Res Clin Oncol 2010; 136:883-889.
22. Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med 2007; 48:932-945. (Pubitemid 46909922)
23. Allal AS, Dulguerov P, Allaoua M, Haenggeli CA, El-Ghazi el A, Lehmann W, et al. Standardized uptake value of 2-[(18)F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol 2002; 20:1398-1404. (Pubitemid 34177448)
24. Halfpenny W, Hain SF, Biassoni L, Maisey MN, Sherman JA, McGurk M. FDG-PET A possible prognostic factor in head and neck cancer. Br J Cancer 2002; 86:512-516. (Pubitemid 34185084)
25. Inokuchi H, Kodaira T, Tachibana H, Nakamura T, Tomita N, Nakahara R, et al. Clinical usefulness of [(18)F] Fluoro-2-deoxy-D-Glucose uptake in 178 headand-neck cancer patients with nodal metastasis treated with definitive chemoradiotherapy: consideration of its prognostic value and ability to provide guidance for optimal selection of patients for planned neck dissection. Int J Radiat Oncol Biol Phys 2011; 79:747-755.
26. Liao CT, Wang HM, Chang JT, Lin CY, Ng SH, Huang SF, et al. Influence of pathological nodal status and maximal standardized uptake value of the primary tumor and regional lymph nodes on treatment plans in patients with advanced oral cavity squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2010; 77:421-429.
27. Allal AS, Slosman DO, Kebdani T, Allaoua M, Lehmann W, Dulguerov P. Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2-deoxy-D-glucose. Int J Radiat Oncol Biol Phys 2004; 59:1295-1300. (Pubitemid 38954050)
28. Kubicek GJ, Champ C, Fogh S, Wang F, Reddy E, Intenzo C, et al. FDG-PET staging and importance of lymph node SUV in head and neck cancer. Head Neck Oncol 2010; 2:19.
29. Xie P, Yue JB, Fu Z, Feng R, Yu JM. Prognostic value of 18F-FDG PET/CT before and after radiotherapy for locally advanced nasopharyngeal carcinoma. Ann Oncol 2010; 21:1078-1082.
30. Liu WS, Wu MF, Tseng HC, Liu JT, Weng JH, Li YC, et al. The role of pretreatment FDG-PET in nasopharyngeal carcinoma treated with intensitymodulated radiotherapy. Int J Radiat Oncol Biol Phys 2011 doi:10.1016/j.ijrobp.2010.11. 055.
31. Chan AT, Felip E. Nasopharyngeal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 (Suppl 4):123-125.
32. Imamura Y, Azuma K, Kurata S, Hattori S, Sasada T, Kinoshita T, et al. Prognostic value of SUVmax measurements obtained by FDG-PET in patients with non-small cell lung cancer receiving chemotherapy. Lung Cancer 2011; 71:49-54.
33. Nakamura H, Hirata T, Kitamura H, Nishikawa J. Correlation of the standardized uptake value in FDG-PET with the expression level of cellcycle-related molecular biomarkers in resected non-small cell lung cancers. Ann Thorac Cardiovasc Surg 2009; 15:304-310.